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, and one of the blisters was removed with intact skin for histologic examination. A subcorneal blister filled with erythrocytes and erythrocyte extravasation in the superficial dermis was revealed on hematoxylin and eosin staining ( Figure 1B) . There was no evidence suggesting skin necrosis or vasculitides, such as infiltration of vessel walls by neutrophils, thrombosis, or fibrin extravasation ( Figure 1C) . Consequently, the biopsy revealed bullous hemorrhagic dermatosis. During follow -up, the INR value decreased to the therapeutic range (2.1) after adjusting warfarin dosage, and the lesions regressed spontaneously ( Figure 1D) .
Hemorrhagic dermatosis is a rare clinical disorder, which is usually associated with treatment with unfractionated heparin 1 or low-molecularweight heparin. 2 The lesions are histopathologically characterized by intraepidermal bullae without features of vasculitis, thrombosis, or inflammation. Hemorrhagic dermatosis secondary to warfarin treatment is extremely rare, and to the best of our knowledge, this is the second case described in the literature. 3
